Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Over a century ago in Melbourne, Australia, we made a promise to save lives and pr...
Over a century ago in Melbourne, Australia, we ...
At Sesen Bio, we are committed to renewing life for people with cancer. We are a l...
At Sesen Bio, we are committed to renewing life...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
Novartis is reimagining medicine to improve and extend peoples lives. As a leadin...
Novartis is reimagining medicine to improve and...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...
Evelo Biosciences, Inc. is a clinical stage bio...
Join the National Investor Network and get the latest information with your interests in mind.